The offering is one of four biotech IPOs that could price by Friday, and comes during the busiest week for such activity ...

In contrast to Lilly’s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13 ...

Despite some angst over pricing pressure for GLP-1 drugs, Lilly’s bullish projections surpassed consensus estimates, while ...

The funding package ends a partial government shutdown and enacts several healthcare policies, including preserving ...

The agency’s program will be open to pharmaceutical facilities that align with “national priorities.” Elsewhere, a ...

CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...

AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.

A massive overhaul of staffing and review processes have left the agency appearing heavily driven by the Trump administration ...

On a conference call, executives cited “confusion” and declining vaccination rates in the U.S. while discussing a quarterly sales decline and anticipated slower growth in 2026.